Foresite Capital Management V, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001792206

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 9 positions · Total reported value $362.20M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 20.0% · 1 new · 0 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +21.1% · vs SPY +6.2% · Prev Value $271.00M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Foresite Capital Management V, LLC disclosed 9 equity positions with a combined reported value of $362.20M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ALMS ($165.94M), CGON ($76.67M), IRON ($27.36M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Foresite Capital Management V, LLC opened 1 new positions, trimmed 0 and fully exited 1, a turnover rate of 20.0% of positions. The portfolio's overlap with the prior quarter was 80% of names.

The largest new positions opened in Q2 2026 were ODTX ($13.34M).

Of the 1 positions fully exited versus the prior quarter, the largest were MAZE ($773.26K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ODTX ODYSSEY THERAPEUTICS INC · $13.34M

Fully Exited (vs previous quarter)

  • MAZE MAZE THERAPEUTICS INC · prev qtr: $773.26K

Insider Transactions (Form 4)

Latest Foresite Capital Management V, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-08-10 Conversion Latigo Biotherapeutics, Inc. 296,880 — SEC filing
2026-08-10 Conversion Latigo Biotherapeutics, Inc. 195,776 — SEC filing
2026-08-10 Buy Latigo Biotherapeutics, Inc. 140,000 $18.00 SEC filing
2026-08-10 Conversion Latigo Biotherapeutics, Inc. 742,201 — SEC filing
2026-08-10 Conversion Latigo Biotherapeutics, Inc. 1,125,823 — SEC filing
2026-08-10 Conversion Latigo Biotherapeutics, Inc. 445,320 — SEC filing
2026-08-10 Conversion Latigo Biotherapeutics, Inc. 3,117,664 — SEC filing

All insider transactions →

Fund Profile

Foresite Capital Management V, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 9 US equity positions with a combined value of $362.20M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 9 positions · $362.20M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: ALMS (ALUMIS INC) at 45.8%
  • Average position size: $40.24M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 2 added, 1 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund's quarter-over-quarter movements suggest a cautious approach with a focus on healthcare, reflecting a belief in the long-term growth potential of the sector. The slight increase in the number of positions and the addition of a new holding (ODTX) indicates a willingness to explore new opportunities within the healthcare sector. 2. Key Moves: - Added: Odyssey Therapeutics Inc. (ODTX) - This new addition to the portfolio may signal a strategic shift towards early-stage biotech companies. - Increased Position: Pharvaris NV (PHVS) - The substantial increase in Pharvaris' position suggests a significant belief in its potential. - No Change: The positions in ALUMIS INC (ALMS), DISC MEDICINE INC (IRON), HIMS & HERS HEALTH INC (HIMS), EIKON THERAPEUTICS INC (EIKN), and NURIX THERAPEUTICS INC (NRIX) remained steady, indicating confidence in these companies. - Reduced: No holdings were reduced in this quarter. 3. Portfolio Structure: - Passive/Active: The portfolio appears to be more active as it includes a new holding and a significant increase in another, suggesting active management and a focus on finding undervalued or growing opportunities. - Sector Bias: The fund is heavily biased towards the healthcare sector, with 90.25% of the total value in healthcare stocks. - Risk Appetite: The portfolio's risk appetite is moderate to high, given the exposure to biotech and pharmaceutical companies, which are typically riskier but can offer higher returns. 4. Per-Holding One-Liner: - ALMS (ALUMIS INC): A biopharmaceutical company specializing in the development of novel therapies for orphan and rare diseases. - CGON (CG ONCOLOGY INC): A biotechnology company focused on the development of novel cancer immunotherapies. - IRON (DISC MEDICINE INC): A biopharmaceutical company engaged in the research and development of treatments for various diseases, including cancer. - HIMS (HIMS & HERS HEALTH INC): A telemedicine company offering a variety of healthcare services. - PHVS (PHARVARIS N V): A biopharmaceutical company developing therapies for the treatment of orphan and rare genetic diseases. - EIKN (EIKON THERAPEUTICS INC): A biotechnology company focused on the development of treatments for cancer and other diseases. - ODTX (Odyssey Therapeutics Inc.): A biotechnology company focused on the development of novel therapies for rare genetic diseases. - LYEL (LYELL IMMUNOPHARMA INC): A biopharmaceutical company dedicated to the development of therapies for autoimmune and inflammatory diseases. - NRIX (NURIX THERAPEUTICS INC): A biopharmaceutical company engaged in the research and development of treatments for metabolic and endocrine disorders. - (Unverified): The specific benchmark or business of each ETF is not provided, and therefore, it is marked 'unverified'. 5. One-Sentence Style Summary: Foresite Capital Management V, LLC maintained a cautious yet opportunistic approach in Q2 2026, increasing exposure to select healthcare companies and adding a new early-stage biotech holding, while maintaining a strong sector bias towards healthcare.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 5.90M $165.94M 45.81%
45.81%
Hold
2 1.08M $76.67M 21.17%
21.17%
Add
3 374.07K $27.36M 7.55%
7.55%
Hold
4 738.15K $25.59M 7.07%
7.07%
Hold
5 664.14K $22.97M 6.34%
6.34%
Add
6 1.32M $17.21M 4.75%
4.75%
Hold
7 713.11K $13.34M 3.68%
3.68%
New
8 476.39K $6.69M 1.85%
1.85%
Hold
9 265.00K $6.43M 1.77%
1.77%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 89% R 89% F1 89% (modelled on 2026-Q1; 8/10 hit)

Historical Backtest (10 quarters)

Avg precision 90% · recall 85% · F1 87% · avg rank error 1.7 · Top-10 turnover 13%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% HIMS · THRX · IRON · KNTE · ME HIMS · CGON · IRON · KNTE · ME
2024-Q2 60% 60% 60% HIMS · CGON · IRON · KNTE · ME ALMS · HIMS · CGON · IRON · CGEM
2024-Q3 100% 100% 100% ALMS · HIMS · CGON · IRON · CGEM ALMS · HIMS · CGON · IRON · CGEM
2024-Q4 100% 83% 91% ALMS · HIMS · CGON · IRON · CGEM ALMS · HIMS · CGON · IRON · CGEM · LYEL
2025-Q1 83% 83% 83% ALMS · HIMS · CGON · IRON · CGEM · LYEL ALMS · CGON · IRON · HIMS · LYEL · MAZE
2025-Q2 100% 100% 100% ALMS · CGON · IRON · HIMS · LYEL · MAZE CGON · ALMS · IRON · HIMS · MAZE · LYEL
2025-Q3 100% 100% 100% CGON · ALMS · IRON · HIMS · MAZE · LYEL CGON · ALMS · IRON · HIMS · LYEL · MAZE
2025-Q4 100% 86% 92% CGON · ALMS · IRON · HIMS · LYEL · MAZE ALMS · CGON · IRON · NTRA · LYEL · HIMS · MAZE
2026-Q1 86% 67% 75% ALMS · CGON · IRON · NTRA · LYEL · HIMS · MAZE ALMS · CGON · IRON · HIMS · EIKN · LYEL · PHVS · NRIX · MAZE
2026-Q2 ★ 89% 89% 89% ALMS · CGON · IRON · HIMS · EIKN · LYEL · PHVS · NRIX · MAZE ALMS · CGON · IRON · HIMS · PHVS · EIKN · ODTX · LYEL · NRIX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Foresite Capital Management V, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Foresite Capital Management V, LLC reported 9 equity positions worth $362.20M in aggregate; its largest disclosed positions were ALMS ($165.94M), CGON ($76.67M), IRON ($27.36M).

How large is Foresite Capital Management V, LLC's portfolio?

Foresite Capital Management V, LLC reported $362.20M of long equity holdings across 9 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Foresite Capital Management V, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/foresite-capital-management-v/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →